There are, however, other serpins that act to control coagulation enzymes, such as heparin cofactor II HC-II, protease nexin I and C1-inhibitor.. A feature of many of the serpins that co
Trang 1Control of the coagulation system by serpins
Getting by with a little help from glycosaminoglycans
Robert N Pike1,2, Ashley M Buckle1,2, Bernard F le Bonniec3and Frank C Church4
1 Department of Biochemistry & Molecular Biology and Co-operative Research Centres for Vaccine Technology and Oral Health Sciences, Monash University, Clayton, Victoria, Australia
2 The Victorian Bioinformatics Consortium, Monash University, Clayton, Victoria, Australia
3 INSERM U428, Faculte´ de Pharmacie, Universite´ Paris V, Paris, France
4 Departments of Pathology and Laboratory Medicine, Pharmacology, and Medicine, Carolina Cardiovascular Biology Center,
The University of North Carolina at Chapel Hill, School of Medicine, NC, USA
Introduction
Efficient functioning of the coagulation system is vital
to human health [1] However, control of this system,
in particular its regulation to prevent inappropriate,
excessive or mislocalized clotting of blood, is also vital
to prevent cardiovascular diseases such as deep vein
thrombosis
Because many of the principal procoagulant
compo-nents of the system are serine proteases, regulation of
the system is principally by the action of serine protease
inhibitors One major class of serine protease inhibitors
regulating procoagulant enzymes is the serpin super-family [2] The principal inhibitor of procoagulant enzymes such as thrombin and factor Xa is the serpin antithrombin (AT) There are, however, other serpins that act to control coagulation enzymes, such as heparin cofactor II (HC-II), protease nexin I and C1-inhibitor Some serpins, such as protein C inhibitor (PCI), act to control the action of anticoagulant enzymes, such as activated protein C
A feature of many of the serpins that control enzymes in the coagulation system is that they them-selves are under the control of glycosaminoglycans
Keywords
antithrombin; coagulation;
glycosaminoglycans; heparin cofactor II;
proteases; protein C inhibitor; serpins;
thrombin
Correspondence
R N Pike, Department of Biochemistry &
Molecular Biology, Monash University,
Clayton, Victoria 3800, Australia
Fax: +61 3 99054699
Tel: +61 3 99053923
E-mail: rob.pike@med.monash.edu.au
(Received 16 December 2004, accepted 14
July 2005)
doi:10.1111/j.1742-4658.2005.04880.x
Members of the serine protease inhibitor (serpin) superfamily play import-ant roles in the inhibition of serine proteases involved in complex systems This is evident in the regulation of coagulation serine proteases, especially the central enzyme in this system, thrombin This review focuses on three serpins which are known to be key players in the regulation of thrombin: antithrombin and heparin cofactor II, which inhibit thrombin in its pro-coagulant role, and protein C inhibitor, which primarily inhibits the throm-bin⁄ thrombomodulin complex, where thrombin plays an anticoagulant role Several structures have been published in the past few years which have given great insight into the mechanism of action of these serpins and have significantly added to a wealth of biochemical and biophysical studies carried out previously A major feature of these serpins is that they are under the control of glycosaminoglycans, which play a key role in acceler-ating and localizing their action While further work is clearly required
to understand the mechanism of action of the glycosaminoglycans, the bio-logical mechanisms whereby cognate glycosaminoglycans for each serpin come into contact with the inhibitors also requires much further work in this important field
Abbreviations
AT, antithrombin; GAG, glycosaminoglycan; HC-II, heparin cofactor II; PCI, protein C inhibitor; serpin, serine protease inhibitor.
Trang 2(GAGs) [3] Glycosaminoglycans such as heparin,
hep-aran sulfate and dermatan sulfate have been found to
significantly accelerate the interaction between serpins
and coagulation proteases, usually increasing the
reac-tion rates from values that are not relevant under
phy-siological conditions to rates that are relevant This
control over the action of serpins that have the
partic-ular role of regulating procoagulant enzymes is
prob-ably vital in that it allows the enzymes to act, as they
must, to clot blood It follows that the serpins mostly
act to localize the clotting process, which is likely to
be the crucial element in the regulation of clotting, and
also to the eventual shutting off of the clotting process,
although this latter element is most probably a
com-plex multifactorial process also involving the platelets
and endothelium
This review will examine the basic elements of the
structure and function of the serpins involved in
con-trolling the central coagulation enzyme, thrombin, and
their control by GAGs Control over other enzymes,
such as factor Xa, will also be mentioned where
rele-vant We will focus on antithrombin, heparin cofactor
II and protein C inhibitor
General mechanism of serpin action
Serpins are a highly evolved family of proteins, which
have a mechanism of action that appears to be
com-mon to most members of the family [4] The
mechan-ism, hotly debated for many years, involves the attack
of the protease on the P1-P1¢ bond in the reactive
cen-tre loop (RCL) of the serpin [5] The catalysis of the
peptide bond cleavage appears to be arrested at the
acyl intermediate by the unique action of the serpin,
whereby the RCL of the serpin inserts into the major
A b-sheet causing the protease to be rapidly
translo-cated from the top to the bottom of the inhibitor [6]
In the process, the structure of the protease appears to
be deformed by being ‘crushed’ against the bottom of
the inhibitor [7] In particular, this deformation of the
protease affects the geometry of the catalytic triad,
preventing the completion of catalysis beyond the acyl
intermediate and therefore trapping the protease in a
covalent bond with the serpin The mechanism is a
sui-cide substrate mechanism, irreversibly inactivating the
serpin The serpin–enzyme complex is later removed
from the circulation by the action of receptors which
specifically recognize the inhibited conformation of the
serpin (reviewed in [4])
The structure and mechanism of serpins is highly
amenable to control via binding of molecules such as
GAGs, but the same level of conformational mobility
which aids in the function of serpins also renders them
susceptible to mutations which cause the A b-sheet in particular to become susceptible to insertion of the ser-pin’s own RCL This results in either a so-called latent state, or in polymers of serpins, where the insertion of another molecule’s RCL takes place [8] Both of these result in the irreversible inactivation (generally) of the serpins, and, in the case of the anticoagulant serpins, a lowering of the effective concentration of the serpins and therefore diseases such as thrombosis [8]
Antithrombin Antithrombin is arguably the major anticoagulant ser-pin It is a 58 kDa glycoprotein, which circulates in blood at a concentration of 125 lgÆmL)1 (2.3 lm) [9] AT inhibits a large number of serine proteases of the coagulation system including thrombin (factor IIa) and factors IXa, Xa, XIa and XIIa The princi-pal targets of the serpin are usually regarded as being thrombin and factor Xa, although it is likely that inhibition of the other enzymes by this serpin is also important
The serpin has a structure (Fig 1) which is highly similar to that of other serpins, with a few important features In its native state the RCL is partially inser-ted into the top of the A b-sheet of the molecule [10] Upon the addition of heparin, the RCL is expelled from the A b-sheet by a closing of the sheet caused by
a conformational transition in the molecule following the binding of a specific heparin pentasaccharide sequence to a highly positively charged cluster located
at the D-helix of the serpin [11,12] The pentasaccha-ride sequence of heparin on its own is able to induce the conformational change in AT [13,14] and this change in the structure of the serpin is apparently able
to substantially accelerate the interaction with serine proteases such as factor Xa, but not enzymes such as thrombin [15] It is thought that the overall increase in the rate of interaction with factor Xa brought about
by the heparin pentasaccharide-mediated conforma-tional change occurs through a combination of the changes in the structure of the RCL, allowing the interaction of residues on the RCL with subsites in the active site of fXa [16,17], and the exposure of a new exosite on the serpin for interaction with the protease [18,19] Given the plasma concentration of AT and the rates of interaction in the presence and absence of hep-arin pentasaccharide (Table 1), one can calculate that the half-life of enzyme activity in the absence of hep-arin pentasaccharide would be 133 s (full lifetime,
22 min), and this would be 1.33 s in the presence
of heparin pentasaccharide (full lifetime, 0.22 min) This action of the synthetic heparin pentasaccharide is
Trang 3apparently effective enough, and has allowed its
intro-duction as a new antithrombotic drug [20]
Heparin pentasaccharide on its own does not
sub-stantially increase the rate of inhibition of some
coagu-lation enzymes, such as thrombin, indicating that the
conformational change in AT alone does not cause
much acceleration in the rate of interaction [15] For
full acceleration of the rate of inhibition of enzymes
such as thrombin, full-length heparin (> 26 saccharide
units in length) is required The longer chains of
hep-arin appear to accelerate the interaction between AT
and thrombin by ‘templating’ the serpin and enzyme,
binding to both molecules (via an exosite on the
prote-ase) and facilitating their diffusion towards each other
in solution [21] This accelerates the interaction of AT with thrombin 1000-fold and with fXa 10 000-fold [22] With regard to the latter interaction, it is clear that calcium ions are required to overcome the negat-ive effects of the Gla-domain of factor Xa on the tem-plating interaction mediated by heparin For thrombin, this means that AT controls the enzyme in 0.27 s in the presence of heparin, compared to 4.4 min in the absence of heparin Clearly this is important, as the impairment of heparin binding on mutants of AT has disease-causing consequences [23] Recently, the struc-ture of AT templated to a genetically modified form of thrombin by a synthetic heparin has been solved [24,25] These structures have supported much of what
Native Antithrombin - Heparin Native Antithrombin
Cleaved Protein C Inhibitor Native Heparin Cofactor 2
Fig 1 The structures of serpins controlling thrombin The structures of AT with and without the heparin pentasaccharide bound, heparin cofactor II and cleaved protein C inhibitor are shown as indicated In all of the structures, the A b-sheet is shown in red, the B b-sheet in green and the C b-sheet in yellow The reactive centre loop is shown in magenta and the D-helix in dark blue The H-helix is shown in dark pink in the protein
C inhibitor structure Positively charged resi-dues on the D- and H-helices and the hep-arin pentasaccharide are shown in ball and stick format.
Trang 4has been published before in terms of the mechanism
by which templating occurs and have provided
addi-tional insights into the conformation of the reactive
centre loop of AT when it is in complex with a target
protease
It is interesting to note that clot bound thrombin
and factor Xa are protected from inactivation by AT
[26,27] This is consistent with the role of AT in
local-izing the clot and preventing it from spreading too far,
rather than actually shutting down clotting It would
appear that AT might localize to clots due to the
expo-sure of heparan sulfate chains on the endothelium
following vascular disruption or the localized release
of heparin from the granules of mast cells which are
found lining the vasculature [28,29] Thus the AT may
act as a sentinel to prevent escape of active
procoagu-lant enzymes from their site of action, allowing
clot-ting to proceed where it is required, but not allowing it
to spread
Antithrombin is clearly critical to survival
Homo-zygous null mutants of AT die in utero [30] and
hetero-zygous mutants which have about 50% of the normal
concentrations of AT are predisposed towards disease
[31] The experiments using the genetically manipulated
mice have confirmed a host of studies which reveal that
mutations of AT which impair its normal function
predispose patients to thrombotic disorders [8],
partic-ularly when found in combination with other
predispo-sing factors [32]
Heparin cofactor II Heparin cofactor II mRNA has been detected only in human liver, and the normal concentration of HC-II
in blood plasma is 1.2 lm and the mature protein is 65.6 kDa [33] The HC-II reactive site peptide bond is Leu444-Ser445 [34,35] Intriguingly, HC-II is a very specific inhibitor of thrombin, but no other serine pro-tease in blood coagulation; however, it does exhibit some inhibitory action to the chymotrypsin-like pro-teases, cathepsin G and chymotrypsin [36,37]
Heparin cofactor II rapidly inhibits thrombin fol-lowing binding to GAGs (Table 1) However, the GAG specificity of HC-II is much less discriminating than that of AT While both heparin⁄ heparan sulfate and dermatan sulfate GAGs are physiological activa-tors of HC-II, many different polyanions, including polyphosphates, polysulfates and polycarboxylates, are able to accelerate HC-II inhibition of thrombin [38,39] The GAG binding site of HC-II has been identified as the D-helix region [40–52] The effects of mutagenesis
of thrombin anion-binding exosites-1 and -2 on GAG acceleration of the HC-II–thrombin reaction suggest that the template mechanism makes only a minor con-tribution to heparin acceleration and no concon-tribution
to dermatan sulfate acceleration [42,45,49,50,53] Instead, the major mechanism of GAG enhancement appears to be allosteric and uses conformational acti-vation of the serpin Heparin cofactor II possesses a unique amino-terminal extension that contains two tandem repeats rich in acidic amino acids with two sul-fated tyrosines (contained in the region encompassed
by residues 54–75) The acidic region repeats of HC-II are significantly homologous to the carboxyl-terminal sequence of hirudin (the thrombin inhibitor from the medicinal leech), which binds to thrombin anion-bind-ing exosite-1 [54,55] Glycosaminoglycan bindanion-bind-ing to HC-II is thought to allosterically activate the serpin
by displacing the acidic amino terminus from an intra-molecular interaction with the basic GAG binding site and freeing it for binding to the thrombin anion-bind-ing exosite-1 [44,46,47,51] An alternative allosteric mechanism has been suggested based on the recently described crystal structures of both native HC-II (Fig 1) and HC-II complexed with catalytically inac-tive S195A thrombin [40] In a surprising revelation, the native HC-II structure showed that the hinge of the reactive centre loop is partially inserted into the A b-sheet, similar to the situation seen in native AT, and the short segment of the amino terminus that was visi-ble suggested that this region might be interacting with
an alternative basic site on the serpin near the reactive loop [40] Thus, GAG activation of HC-II was
Table 1 Second order rates of association (kass) values for the
reaction of serpins with proteases in the presence and absence of
a range of GAGs (values are representative of those reported in a
range of publications cited in this article).
Serpin Enzyme Glycosaminoglycan kass( M )1Æs)1)
Antithrombin Thrombin – 1 · 10 4
Heparin 4 · 10 7
Heparan 2 · 10 7
High affinity heparin 4 · 10 7
Heparin pentasaccharide 2 · 10 4
Factor Xa – 2 · 10 3
Heparin 4 · 10 7
Heparan 2 · 10 7
High affinity heparin 4 · 10 7
Heparin pentasaccharide 5 · 10 5
HCII Thrombin – 7 · 10 2
Dermatan sulfate 1 · 10 7
Heparin 1 · 10 7
PCI Thrombin Heparin 5 · 10 5
fXa Heparin 3 · 10 3
Heparin 2 · 10 4
Heparin ⁄ calcium 3 · 10 6
Trang 5proposed to resemble AT, where GAG binding to the
D-helix causes the expulsion of the buried reactive
cen-tre loop hinge from the A b-sheet, which in turn alters
the amino-terminal tail interaction to promote binding
to the thrombin anion-binding exosite-1 Regardless of
which allosteric mechanism turns out to be more
cor-rect, it is obvious that release of the amino-terminal
portion of HC-II to bind to thrombin anion-binding
exosite-1 is a primary part of the allosteric activation
mechanism
For many years, the physiological activator of HC-II
has been assumed to be extravascular dermatan sulfate
[56–64], which would complement the intravascular
effect of heparan sulfate binding to AT Maimone and
Tollefsen [60] described the structure of a high affinity
dermatan sulfate hexasaccharide that bound to HC-II
Furthermore, dermatan sulfate proteoglycans on the
surface of cultured fibroblasts and vascular smooth
muscle cells and purified biglycan and decorin
derma-tan sulfate proteoglycans accelerate the rate of
throm-bin inhibition by HC-II [58,62] Dermatan sulfate
proteoglycans in the extracellular matrices and on
cer-tain cell surfaces may localize HC-II to sites
appropri-ate for inhibiting thrombin The murine knock-out
studies of HC-II revealed a role for this serpin in
regu-lating thrombin formation, especially in the arterial
cir-culation [65] Recent studies using HC-II deficient mice
confirmed that the antithrombotic effect of exogenously
added dermatan sulfate is due to its interaction with
HC-II [66] Collectively, these findings imply that
HC-II has a major role in thrombin regulation at
extra-vascular tissue sites following vessel injury
Protein C inhibitor (also named PAI-3)
Protein C inhibitor antigen is found in human blood
plasma (3.6–6.8 lgÆmL)1 or 90 nm) [67], numerous
other human tissues, in urine and several other body
fluids (e.g tears, saliva, cerebral spinal fluid, amniotic
fluid), and in seminal fluid at 200 lgÆmL)1, which is
almost 40 times the amount in plasma [68–76] The
mature protein is 57 kDa [77,78] The PCI reactive site
peptide bond is Arg354-Ser355, and PCI displays a
protease inhibition profile for numerous
‘arginine-specific’ serine proteases, including trypsin, thrombin
(in the absence and presence of thrombomodulin),
acti-vated protein C, acrosin, kallikrein, urokinase, tissue
plasminogen activator and factor XIa [69–71,74,77–
91] The GAG binding site in protein C inhibitor
appears to be localized not to the D-helix as in AT
and HC-II, but to the H-helix region, with possible
contributions from the N-terminal A+-helix region
[92–96] Both regions have sequences of basic residues
consistent with a general heparin-binding consensus sequence motif Mutagenesis of four basic residues in the H-helix, Lys266, Arg269, Lys270 and Lys273, in recombinant PCI has shown that all of these residues are important for heparin binding With the recent report of the crystal structure of cleaved-PCI (Fig 1) [97], there are clearly other basic residues near the pri-mary H-helix GAG binding site that probably contri-bute to GAG⁄ polyanion binding (including Arg26, Arg27, Arg213, Arg234, Arg229, Lys255 and Arg362)
In contrast to both AT and HC-II, there is no evidence for an allosteric activation mechanism and instead the mechanism appears to involve only a ternary complex with heparin bridging the serpin and protease [61,98] As found for other serine pro-teases with c-carboxyglutamic acid domains, heparin bridging of PCI and activated protein C is only modest unless calcium ions are present to bind the acidic domain and prevent its interaction with the heparin-binding site of the protease [89,91] Throm-bin is also inhibited by PCI and the inhibition is accelerated by heparin, but the heparin-enhanced rate does not appear to be physiologically relevant when compared to thrombin inhibition rates by both AT-heparin⁄ heparan sulfate and HC-II-heparin⁄ dermatan sulfate A more physiologically significant rate of thrombin inhibition by PCI results when thrombin binds to thrombomodulin, the endothelial cell receptor⁄ proteoglycan [84,86,90,99] This is con-sistent with PCI regulating the anticoagulant protein
C pathway, because the thrombin-thrombomodulin complex initiates this pathway by the activation of zymogen protein C to an anticoagulant serine prote-ase Interestingly, the increased rate of thrombin inhibition when bound to thrombomodulin that is measured with PCI does not involve the chondroitin sulfate moiety of thrombomodulin, but rather is apparently promoted by the epidermal growth factor-like domains of thrombomodulin
Like HC-II, PCI has a broad GAG⁄ polyanion specificity for acceleration of protease inhibition reac-tions [61,98] A variety of GAGs and polyanions [including heparin, low molecular weight heparin, heparan sulfate, fucoidan, and other polyanions (phosvitin)] accelerate both thrombin and activated protein C inhibition by PCI; this is consistent with a relatively nonspecific heparin-binding site in protein
C inhibitor In contrast to AT, there is no evidence for any sequence-specific binding of heparin⁄ heparan sulfate to PCI In a cell-derived series of studies, heparan sulfate-containing proteoglycans were involved in binding to PCI using cultured human epithelial kidney tumor cells (TCL-598); furthermore,
Trang 6dermatan sulfate-containing proteoglycans were
impli-cated in binding PCI in the extracellular matrix
[70,100] However, identification of the physiological
proteoglycan responsible for acceleration of PCI’s
activity in vivo has not been clearly identified
Overall conclusions and future
directions
It is readily apparent that the action of the three
ser-pins discussed here is highly controlled by interactions
with GAGs There are differences in the way which
each of the three serpins bind the GAGs, but common
to each is that GAGs increase the rate of interaction
with target proteases The interaction of AT with
hep-arin is clearly the most understood in structural terms,
although a number of elements of the conformational
change brought about in AT by heparin remain a little
unclear Further structural studies are obviously
required to fully understand the interaction of HC-II
and PCI with cognate GAGs
The action of GAGs, in particular that of heparin
on AT, has been very successfully exploited in clinical
practice and this has been brought to even greater
sophistication by the introduction of synthetic
ana-logues of heparin There is still a great need to fully
understand the situation in the physiological setting,
however It is not completely clear when each serpin
comes into contact with the GAGs that modulate its
activity and how this leads to the vital regulation
which evidently occurs This is a major area of basic
research for the immediate and medium term future
Acknowledgements
This work was supported by the National Health &
Medical Research Council of Australia, the
Austra-lian Research Council, the National Heart
Founda-tion of Australia (to RNP and AMB), Research
Grants HL-06350 and HL-32656 from the National
Institutes of Health (to FCC), the Institut National
de la Sante´ et de la Recherche Me´dicale of France
and the Foundation pour la Recherche Me´dicale of
France (to BFLB)
References
1 Spronk HM, Govers-Riemslag JW & ten Cate H
(2003) The blood coagulation system as a molecular
machine BioEssays 25, 1220–1228
2 Silverman GA, Bird PI, Carrell RW, Church FC,
Coughlin PB, Gettins PGW et al (2001) The serpins
are an expanding superfamily of structurally similar
but functionally diverse proteins: Evolution, mechan-ism of inhibition, novel functions, and a revised nomenclature J Biol Chem 276, 33293–33296
3 Huntington JA (2003) Mechanisms of glycosaminogly-can activation of the serpins in hemostasis J Thromb Haemost 1, 1535–1549
4 Gettins PG (2002) Serpin structure, mechanism, and function Chem Rev 102, 4751–4804
5 Ye S, Cech AL, Belmares R, Bergstrom RC, Tong Y, Corey DR, Kanost MR & Goldsmith EJ (2001) The structure of a Michaelis serpin-protease complex Nat Struct Biol 8, 979–983
6 Kaslik G, Kardos J, Szabo E, Szilagyi L, Zavodszky P, Westler WM, Markley JL & Graf L (1997) Effects of serpin binding on the target proteinase: global stabili-zation, localized increased structural flexibility, and conserved hydrogen bonding at the active site
Biochemistry 36, 5455–5464
7 Huntington JA, Read RJ & Carrell RW (2000) Struc-ture of a serpin-protease complex shows inhibition by deformation, Nature 407
8 Stein PE & Carrell RW (1995) What do dysfunctional serpins tell us about molecular mobility and disease? Struct Biol 2, 96–113
9 Conard J, Brosstad F, Lie Larsen M, Samama M & Abildgaard U (1983) Molar antithrombin concentra-tion in normal human plasma Haemostasis 13, 363– 368
10 Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW & Wardell MR (1997) The 2.6 A structure
of antithrombin indicates a conformational change at the heparin binding site J Mol Biol 266, 601–609
11 Huntington JA, Olson ST, Fan B & Gettins PG (1996) Mechanism of heparin activation of antithrombin Evidence for reactive center loop preinsertion with expulsion upon heparin binding Biochemistry 35, 8495–8503
12 Jin L, Abrahams JP, Skinner R, Petitou M & Pike RN (1997) The anticoagulant activation of antithrombin by heparin Proc Natl Acad Sci USA 94, 14683–14688
13 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B & Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity Biochem Biophys Res Commun 116, 492–499
14 Desai UR, Petitou M, Bjork I & Olson ST (1998) Mechanism of heparin activation of antithrombin Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin J Biol Chem 273, 7478–7487
15 Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD & Choay J (1992) Role of the antithrombin-binding penta-saccharide in heparin acceleration of antithrombin-proteinase reactions Resolution of the antithrombin
Trang 7conformational change contribution to heparin rate
enhancement J Biol Chem 267, 12528–12538
16 Quinsey NS, Whisstock JC, Le Bonniec B, Louvain V,
Bottomley SP & Pike RN (2002) Molecular determinants
of the mechanism underlying acceleration of the
inter-action between antithrombin and factor Xa by heparin
pentasaccharide J Biol Chem 277, 15971–15978
17 Rezaie AR, Yang L & Manithody C (2004)
Mutagen-esis studies toward understanding the mechanism of
differential reactivity of factor Xa with the native and
heparin-activated antithrombin Biochemistry 43, 2898–
2905
18 Chuang YJ, Swanson R, Raja SM & Olson ST (2001)
Heparin enhances the specificity of antithrombin for
thrombin and factor Xa independent of the reactive
center loop sequence Evidence for an exosite
determi-nant of factor Xa specificity in heparin-activated
antithrombin J Biol Chem 276, 14961–14971
19 Izaguirre G, Zhang W, Swanson R, Bedsted T & Olson
ST (2003) Localization of an antithrombin exosite that
promotes rapid inhibition of factors Xa and IXa
dependent on heparin activation of the serpin J Biol
Chem 278, 51433–51440
20 The Rembrandt Investigators (2000) Treatment of
proximal deep vein thrombosis with a novel synthetic
compound (SR90107A⁄ ORG31540) with pure
anti-fac-tor Xa activity: a phase II evaluation Circulation 102,
2726–2731
21 Olson ST & Shore JD (1982) Demonstration of a
two-step reaction mechanism for inhibition of
alpha-throm-bin by antithromalpha-throm-bin III and identification of the step
affected by heparin J Biol Chem 257, 14891–14895
22 Rezaie AR (1998) Calcium enhances heparin catalysis
of the antithrombin-Factor Xa reaction by a template
mechanism: Evidence that calcium alleviates Gla
domain antagonism of heparin binding to Factor Xa
J Biol Chem 273, 16824–16827
23 Lane DA, Olds R & Thein S-L (1992) Antithrombin and
its deficiency states Blood Coag Fibrinol 3, 315–341
24 Li W, Johnson DJ, Esmon CT & Huntington JA
(2004) Structure of the antithrombin-thrombin-heparin
ternary complex reveals the antithrombotic mechanism
of heparin, Nat Struct Mol Biol 11, 857–862
25 Dementiev A, Petitou M, Herbert JM & Gettins PG
(2004) The ternary complex of
antithrombin-anhydro-thrombin-heparin reveals the basis of inhibitor
specifi-city Nat Struct Mol Biol 11, 863–867
26 Weitz JI, Hudoba M, Massel D, Maraganore J &
Hirsh J (1990) Clot-bound thrombin is protected from
inhibition by heparin-antithrombin III but is
suscepti-ble to inactivation by antithrombin III-independent
inhibitors J Clin Invest 86, 385–391
27 Rezaie AR (2001) Prothrombin protects factor Xa in
the prothrombinase complex from inhibition by the
heparin-antithrombin complex Blood 97, 2308–2313
28 Mertens G, Cassiman J-J, Van den Berghe H, Vermy-len J & David G (1992) Cell surface heparan sulfate proteoglycans from human vascular endothelial cells: core protein characterization and antithrombin III binding properties J Biol Chem 267, 20435–20443
29 Scully MF, Ellis V, Shah N & Kakkar V (1989) Effect
of a heparan sulphate with high affinity for antithrom-bin III upon inactivation of thromantithrom-bin and coagulation factor Xa Biochem J 262, 651–658
30 Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M et al (2000) Complete antithrom-bin deficiency in mice results in embryonic lethality
J Clin Invest 106, 873–878
31 Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Matsushita T et al (2002) Impact of antithrombin deficiency in thrombogenesis: lipopolysac-charide and stress-induced thrombus formation in het-erozygous antithrombin-deficient mice Blood 99, 2455– 2458
32 Beauchamp NJ, Pike RN, Daly M, Butler L, Markis
M, Daffron TR et al (1998) Antithrombins Wibble and Wobble (T85M⁄ K): Archetypal conformational diseases with in vivo latent-transition, thrombosis and heparin activation Blood 92, 2696–2706
33 Tollefsen DM & Pestka CA (1985) Heparin cofactor II activity in patients with disseminated intravascular coa-gulation and hepatic failure Blood 66, 769–774
34 Blinder MA, Marasa JC, Reynolds CH, Deaven LL & Tollefsen DM (1988) Heparin cofactor II: cDNA sequence, chromosome localization, restriction frag-ment length polymorphism, and expression in Escheri-chia coli Biochem 27, 752–759
35 Griffith MJ, Noyes CM, Tyndall JA & Church FC (1985) Structural evidence for leucine at the reactive site of heparin cofactor II Biochemistry 24, 6777–6782
36 Church FC, Noyes CM & Griffith MJ (1985) Inhibi-tion of chymotrypsin by heparin cofactor II Proc Natl Acad Sci USA 82, 6431–6434
37 Parker KA & Tollefsen DM (1985) The protease specifi-city of heparin cofactor II Inhibition of thrombin gener-ated during coagulation J Biol Chem 260, 3501–3505
38 Pratt CW, Whinna HC, Meade JM, Treanor RE & Church FC (1989) Physicochemical aspects of heparin cofactor II Ann NY Acad Sci 556, 104–114
39 Tollefsen DM (1997) Heparin cofactor II Adv Exp Med Biol 425, 35–44
40 Baglin TP, Carrell RW, Church FC, Esmon CT & Huntington JA (2002) Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multi-step allosteric mechanism Proc Natl Acad Sci USA 99, 11079–11084
41 Blinder MA & Tollefsen DM (1990) Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II J Biol Chem 265, 286–291
Trang 842 Fortenberry YM, Whinna HC, Gentry HR, Myles T,
Leung LL & Church FC (2004) Molecular mapping of
the thrombin-heparin cofactor II complex J Biol Chem
279, 43237–43244
43 Jeter ML, Ly LV, Fortenberry YM, Whinna HC,
White RR, Rusconi CP, Sullenger BA & Church FC
(2004) RNA aptamer to thrombin binds anion-binding
exosite-2 and alters protease inhibition by
heparin-binding serpins FEBS Lett 568, 10–14
44 Liaw PCY, Austin RC, Fredenburgh JC, Stafford AR
& Weitz JI (1999) Comparison of heparin- and
derma-tan sulfate-mediated catalysis of thrombin inactivation
by heparin cofactor II J Biol Chem 274, 27597–27604
45 Myles T, Church FC, Whinna HC, Monard D & Stone
SR (1998) Role of thrombin anion-binding exosite-I in
the formation of thrombin-serpin complexes J Biol
Chem 273, 31203–31208
46 Ragg H, Ulshofer T & Gerewitz J (1990) On the
acti-vation of human leuserpin-2, a thrombin inhibitor, by
glycosaminoglycans J Biol Chem 265, 5211–5218
47 Ragg H, Ulshofer T & Gerewitz J (1990)
Glycosamino-glycan-mediated leuserpin-2⁄ thrombin interaction:
Structure· function relationships J Biol Chem 265,
22386–22391
48 Rogers SJ, Pratt CW, Whinna HC & Church FC
(1992) Role of thrombin exosites in inhibition by
heparin cofactor II J Biol Chem 267, 3613–3617
49 Sheehan JP, Tollefsen DM & Sadler JE (1994) Heparin
cofactor II is regulated allosterically and not primarily
by template effects Studies with mutant thrombins and
glycosaminoglycans J Biol Chem 269, 32747–32751
50 Sheehan JP, Wu Q, Tollefsen DM & Sadler JE (1993)
Mutagenesis of thrombin selectively modulates
inhibi-tion by serpins heparin cofactor II and antithrombin
III Interaction with the anion-binding exosite
deter-mines heparin cofactor II specificity J Biol Chem 268,
3639–3645
51 VanDeerlin VMD & Tollefsen DM (1991) The
N-term-inal acidic domain of heparin cofactor II mediates the
inhibition of a-thrombin in the presence of
glycosami-noglycans J Biol Chem 266, 20223–20231
52 Whinna HC, Blinder MA, Szewczyk M, Tollefsen
DM & Church FC (1991) Role of lysine 173 in
heparin binding to heparin cofactor II J Biol Chem
266, 8129–8135
53 Verhamme IM, Bock PE & Jackson CM (2004) The
preferred pathway of glycosaminoglycan-accelerated
inactivation of thrombin by heparin cofactor II J Biol
Chem 279, 9785–9795
54 Inhorn RC & Tollefsen DM (1986) Isolation and
char-acterization of a partial cDNA clone for heparin
cofac-tor II Biochem Biophys Res Commun 137, 431–436
55 Ragg H (1986) A new member of the plasma protease
inhibitor gene family Nuc Acids Res 14, 1073–1087
56 Tollefsen DM, Pestka CA & Monafo WJ (1983) Acti-vation of heparin cofactor II by dermatan sulfate
J Biol Chem 258, 6713–6716
57 Tollefsen DM, Peacock ME & Monafo WJ (1986) Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II
J Biol Chem 261, 8854–8858
58 McGuire EA & Tollefsen DM (1987) Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells J Biol Chem 262, 169–175
59 Tollefsen DM, Maimone MM, McGuire EA & Pea-cock ME (1989) Heparin cofactor II activation by der-matan sulfate Ann N Y Acad Sci 556, 116–122
60 Maimone MM & Tollefsen DM (1990) Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity J Biol Chem 265, 18263– 18271
61 Pratt CW, Whinna HC & Church FC (1992) A com-parison of three heparin-binding serine proteinase inhi-bitors J Biol Chem 267, 8795–8801
62 Whinna HC, Choi HU, Rosenberg LC & Church FC (1993) Interaction of heparin cofactor II with biglycan and decorin J Biol Chem 268, 3920–3924
63 Shirk RA, Church FC & Wagner WD (1996) Arterial smooth muscle cell heparan sulfate proteoglycans accel-erate thrombin inhibition by heparin cofactor II Arter-ioscler Thromb Vasc Biol 16, 1138–1146
64 Shirk RA, Parthasarathy N, San Antonio JD, Church
FC & Wagner WD (2000) Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human athero-sclerotic plaque J Biol Chem 275, 18085–18092
65 He L, Vicente CP, Westrick RJ, Eitzman DT & Tollef-sen DM (2002) Heparin cofactor II inhibits arterial thrombosis after endothelial injury J Clin Invest 109, 213–219
66 Vicente CP, He L, Pavao MS & Tollefsen DM (2004) Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice Blood 104, 3965–3970
67 Suzuki K, Deyashiki Y, Nishioka J & Toma K (1989) Protein C inhibitor: structure and function Thromb Haemostas 61, 337–342
68 Laurell M & Stenflo J (1989) Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein Thromb Haemostasis 62, 885– 891
69 Espana F, Gruber A, Heeb M, Hanson S, Harker L & Griffin J (1991) In vivo and in vitro complexes of acti-vated protein C with two inhibitors in baboons Blood
77, 1754–1760
70 Geiger M, Priglinger U, Griffin JH & Binder BR (1991) Urinary protein C inhibitor Glycosaminocly-cans synthesized by the epithelial kidney cell line
Trang 9TCL)598 enhance its interaction with urokinase J Biol
Chem 266, 11851–11857
71 Ecke S, Geiger M, Resch I, Jerabek I, Stingl L, Maier
M & Binder BR (1992) Inhibition of tissue kallikrein
by protein C inhibitor Evidence for identity of protein
C inhibitor with the kallikrein binding protein J Biol
Chem 267, 7048–7052
72 Laurell M, Christensson A, Abrahamsson PA, Stenflo
J & Lilja H (1992) Protein C inhibitor in human body
fluids Seminal plasma is rich in inhibitor antigen
deriv-ing from cells throughout the male reproductive
sys-tem J Clin Invest 89, 1094–1101
73 Radtke KP, Fernandez JA, Greengard JS, Tang WW,
Wilson CB, Loskutoff DJ, Scharrer I & Griffin JH
(1994) Protein C inhibitor is expressed in tubular cells
of human kidney J Clin Invest 94, 2117–2124
74 Hermans JM, Jones R & Stone SR (1994) Rapid
bition of the sperm protease acrosin by protein C
inhi-bitor Biochemistry 33, 5440–5444
75 Espana F, Sanchez-Cuenca J, Fernandez PJ, Gilabert
J, Romeu A, Estelles A, Royo M & Muller CH (1999)
Inhibition of human sperm-zona-free hamster oocyte
binding and penetration by protein C inhibitor
Andrologia 31, 217–223
76 Uhrin P, Dewerchin M, Hilpert M, Chrenek P, Schofer
C, Zechmeister-Machhart M et al (2000) Disruption of
the protein C inhibitor gene results in impaired
sperma-togensis and male infertility J Clin Invest 106, 1531–
1539
77 Suzuki K, Nishioka J & Hashimoto S (1983) Protein C
inhibitor: purification from human plasma and
charac-terization J Biol Chem 258, 163–168
78 Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira
M, Yamamoto S & Hashimoto S (1987)
Characteriza-tion of a cDNA for human protein C inhibitor A new
member of the plasma serine protease inhibitor
super-family J Biol Chem 262, 611–616
79 Suzuki K (1984) Activated protein C inhibitor Semin
Thrombos Hemostas 10, 154–161
80 Heeb MJ, Espana F, Geiger M, Collen D, Stump DC
& Griffin JH (1987) Immunological identity of
heparin-dependent plasma and urinary protein C inhibitor and
plasminogen activator inhibitor-3 J Biol Chem 262,
15813–15816
81 Geiger M, Heeb MJ, Binder BR & Griffin JH (1988)
Competition of activated protein C and urokinase for
a heparin-dependent inhibitor FASEB J 2, 2263–2267
82 Meijers JCM, Kanters DHAJ, Vlooswijk RAA, van
Erp HE, Hessing M & Bouma BN (1988) Inactivation
of human plasma kallikrein and factor XIa by protein
C inhibitor Biochemistry 27, 4231–4237
83 Heeb MJ, Espana F & GJ (1989) Inhibition and
com-plexation of activated protein C by two major
inhibi-tors in plasma Blood 73, 446–454
84 Rezaie AR, Cooper ST, Church FC & Esmon CT (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex J Biol Chem 270, 25336–25339
85 Elisen MG, van Kooij RJ, Nolte MA, Marquart JA, Lock TM, Bouma BN & Meijers JC (1998) Protein C inhibitor may modulate human sperm–oocyte interac-tions Biol Reprod 58, 670–677
86 Elisen MG, dem Borne PA, Bouma BN & Meijers
JC (1998) Protein C inhibitor acts as a procoagulant
by inhibiting the thrombomodulin-induced activation
of protein C in human plasma Blood 91, 1542–1547
87 Elisen MGLM, Bouma BN, Church FC & Meijers JCM (1998) Inhibition of serine proteases by reactive site mutants of protein C inhibitor (plasminogen acti-vator inhibitor-3) Fib Prot 12, 283–291
88 Shen L, Villoutreix BO & Dahlback B (1999) Involve-ment of Lys 62 (217) and Lys 63 (218) of human anti-coagulant protein C in heparin stimulation of inhibition
by the protein C inhibitor Thromb Haemost 82, 72–79
89 Friedrich U, Blom AM, Dahlba¨ck B & Villoutreix BO (2001) Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C J Biol Chem 276, 24122–24128
90 Mosnier LO, Elisen MG, Bouma BN & Meijers JC (2001) Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regula-tion of TAFI activaregula-tion Thromb Haemost 86, 1057– 1064
91 Rezaie AR (2003) Exosite-dependent regulation of the protein C anticoagulant pathway Trends Cardiovasc Med 13, 8–15
92 Kuhn LA, Griffin JH, Fisher CL, Greengard JS,
Bou-ma BN, Espana F & Tainer JA (1990) Elucidating the structural chemistry of glycosaminoglycan recognition
by protein C inhibitor Proc Natl Acad Sci USA 87, 8506–8510
93 Shirk RA, Elisen MGLM, Meijers JCM & Church FC (1994) Role of the H helix in heparin binding to pro-tein C inhibitor J Biol Chem 269, 28690–28695
94 Cooper ST, Whinna HC, Jackson TP, Boyd JM & Church FC (1995) Intermolecular interactions between protein C inhibitor and coagulation proteases Bio-chemistry 34, 12991–12997
95 Elisen MGLM, Maseland MHH, Church FC, Bouma
BN & Meijers JCM (1996) Role of the A+ helix in heparin binding to protein C inhibitor Thromb Hae-most 75, 760–766
96 Neese LL, Wolfe CA & Church FC (1998) Contribu-tion of basic residues of the D and H helices in heparin binding to protein C inhibitor Arch Biochem Biophys
355, 101–108
97 Huntington JA, Kjellberg M & Stenflo J (2003) Crystal structure of protein C inhibitor provides insights into
Trang 10hormone binding and heparin activation Structure
(Camb) 11, 205–215
98 Pratt CW & Church FC (1992) Heparin binding to
protein C inhibitor J Biol Chem 267, 8789–8794
99 Yang L, Manithody C, Walston TD, Cooper ST &
Rezaie AR (2003) Thrombomodulin enhances the
reac-tivity of thrombin with protein C inhibitor by
provid-ing both a bindprovid-ing site for the serpin and allosterically
modulating the activity of thrombin J Biol Chem 278, 37465–37470
100 Priglinger U, Geiger M, Bielek E, Vanyek E & Binder BR (1994) Binding of urinary protein C inhibitor to cultured human epithelial kidney tumor cells (TCL-598) The role of glycosaminoglycans pre-sent on the luminal cell surface J Biol Chem 269, 14705–14710